Dykhno A Iu, Kostyleva O I, Gershteĭn E S, Polotskiĭ B E, Kushlinskiĭ N E
Vestn Ross Akad Med Nauk. 1998(5):51-4.
Investigators and clinicians have recently called attention not only to the clinical and morphological parameters, but to the parameters characterizing the biological activity of nonsmall-cell carcinoma of the lung (NSCCL) from biochemical and molecular biological points of view. These include production of epidermal growth factor (EGF) receptors (EGFR) and their ligands which are important auto/paracrine regulation of lung tissue formation in health and tumor growth. Active studies of EGFR and EGF-like peptides (mainly, EGF and alpha-TGF) have failed to gain an insight into their role in the pathogenesis of NSCCL. Most authors suppose that tumor EGFR production increases as cell atypical features enhance and tumors show EGFR hyperexpression as compared with intact lung tissue. The expression of EGF and alpha-TGF is associated with poor prognosis in NSCCL. Attempts at designing and clinically testing the agents that block the transmission of EGFR ligands within the tumor cell are well-known, which open up new possibilities for antitumor therapy of patients with NSCCL.
研究人员和临床医生最近不仅关注临床和形态学参数,还从生化和分子生物学角度关注表征非小细胞肺癌(NSCCL)生物活性的参数。这些参数包括表皮生长因子(EGF)受体(EGFR)及其配体的产生,它们在健康状态下对肺组织形成以及肿瘤生长具有重要的自分泌/旁分泌调节作用。对EGFR和EGF样肽(主要是EGF和α-TGF)的积极研究未能深入了解它们在NSCCL发病机制中的作用。大多数作者认为,随着细胞非典型特征增强,肿瘤EGFR产生增加,与完整肺组织相比,肿瘤呈现EGFR过度表达。EGF和α-TGF的表达与NSCCL的不良预后相关。设计和临床测试阻断肿瘤细胞内EGFR配体传递的药物的尝试是众所周知的,这为NSCCL患者的抗肿瘤治疗开辟了新的可能性。